

SUPPLEMENTAL FIGURE 1. CGRP pre-treatment of bEnd.3 cells biases LC Ag presentation to T cells towards an enhanced IL-17A and IL-6 response with a reduced IFNγ, IL-22 and IL-4 response. Medium- or CGRP-treated bEnd.3 cells were added to cultures of LC, T cells (from DO11.10 Tg mice) and $cOVA_{323-339}$. After 48 hours, supernatants were assessed for cytokine content. Addition of medium-treated bEnd.3 cells significantly enhanced IL-17A, IL-6, IFNγ and IL-22 accompanied by a small but significant decrease in IL-4 production occurred. Addition of CGRP-treated bEnd.3 cells induced a much larger increase in IL-17A and IL-6 production but eliminated the increased production of IFNγ and IL-22 with a further small but significant reduction in IL-4 production compared to that seen in wells with addition of medium-treated bEnd.3 cells. n=4 experiments, all groups. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.



SUPPLEMENTAL FIGURE 2. Pre-treatment of pDMECs with SP or ADM biases LC Ag presentation to T cells with a different pattern of responses compared to CGRP-pre-treated pDMECs. Medium-, CGRP-, SP- or ADM-treated pDEMECs were added to cultures of LC, T cells (from DO11.10 Tg mice) and $cOVA_{323-339}$. After 48 hours, supernatants were assessed for cytokine content. Compared to wells containing medium-treated pDMECs, CGRP treatment resulted in a significant increase in IL-17A and IL-6 production with significantly decreased production of IFNγ, IL-22 and IL-4. SP treatment yielded a tiny but significant increase in IL-17A production, no change in IL-6, IL-22 or IL-4 production and a small but significant decrease in IFNγ production. ADM treatment yielded a tiny but significant increase in IL-17A production, no change in IL-6 production, small but significant decreases in IFNγ and IL-22 production and a very small but significant reduction in IL-4 production. n=3 experiments, all groups. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.



SUPPLEMENTAL FIGURE 3. The effects of CGRP pre-treatment of bEnd.3 cells on LC Ag presentation to T cells can be blocked with $CGRP_{8-37}$. bEnd.3 cells were treated with graded concentrations of $CGRP_{8-37}$ or medium alone during exposure to CGRP followed by washing and addition to cultures of LCs, T cells (from DO11.10 Tg mice) and $cOVA_{323-339}$. After 48 hours, supernatants were assessed for cytokine content. The effects of CGRP on production of IL-17A, IL-6, IFNγ, IL-4 and IL-22 were all significantly inhibited by $CGRP_{8-37}$ in a dose-dependent manner. n=3 experiments, all groups. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.



SUPPLEMENTAL FIGURE 4. Total RNA was extracted from pDMECs of BALB/c mice and RT-PCR for RAMP1, RAMP2, RAMP3, CRLR and CRCP performed. RAMP1, RAMP2, RAMP3, CRLR and CRCP are all expressed as indicated by the presence of a PCR product of the predicted molecular weight.